Search

Your search keyword '"Neuraminidase antagonists & inhibitors"' showing total 57 results

Search Constraints

Start Over You searched for: Descriptor "Neuraminidase antagonists & inhibitors" Remove constraint Descriptor: "Neuraminidase antagonists & inhibitors" Publisher wiley Remove constraint Publisher: wiley
57 results on '"Neuraminidase antagonists & inhibitors"'

Search Results

1. The exploration of neuraminidase inhibitory activity on Fallopia denticulata, an ethnic herb in China.

2. Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase.

3. Anti-neuraminidase activity of chemical constituents of Balanophora involucrata.

4. Use of lentiviral pseudotypes as an alternative to reassortant or Triton X-100-treated wild-type Influenza viruses in the neuraminidase inhibition enzyme-linked lectin assay.

5. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.

6. Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan.

7. Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.

8. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.

10. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.

11. Oseltamivir for the treatment of H1N1 influenza during pregnancy.

12. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.

13. Yu Ping Feng San, an Ancient Chinese Herbal Decoction, Induces Gene Expression of Anti-viral Proteins and Inhibits Neuraminidase Activity.

14. Neuraminidase inhibitors for preventing and treating influenza in adults and children.

15. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.

16. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

17. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.

18. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.

19. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

20. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.

21. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.

22. In vitro selection of sialic acid specific RNA aptamer and its application to the rapid sensing of sialic acid modified sugars.

23. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.

24. Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1.

25. Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.

26. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

27. Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses.

28. Modeling the global transmission of antiviral-resistant influenza viruses.

29. Clinical use of approved influenza antivirals: therapy and prophylaxis.

30. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics.

31. Newer influenza antivirals, biotherapeutics and combinations.

32. Surveillance for antiviral resistance.

33. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.

34. Role of neuraminidase inhibitor chemoprophylaxis in controlling nosocomial influenza: an observational study.

35. Influenza neuraminidase.

36. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).

37. Neuraminidase inhibitors for preventing and treating influenza in children.

38. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

39. Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy.

40. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

41. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.

42. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.

43. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.

44. Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

45. Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers.

46. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design.

47. Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR).

48. Pandemic flu vaccine: are we doing enough?

49. Neuraminidase inhibitors for preventing and treating influenza in children.

50. Neuraminidase inhibitors for preventing and treating influenza in healthy adults.

Catalog

Books, media, physical & digital resources